Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gallbladder cancer
Stage/Subtype:  recurrent gallbladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-17 of 17 for your search:
Start Over
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CDM00047339, NCI-2016-00348, E7059, NCT01774019
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy and Pembrolizumab in Treating Patients with Metastatic Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, 306343, P09567, NCT01174121
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Copanlisib, Gemcitabine, and Cisplatin in Treating Patients with Advanced Cholangiocarcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18435, NCI-2016-01029, NCT02631590
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16329, NCI-2016-01171, 2015-004699-31, I3O-MC-JSBF, NCT02711553
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18684, NCI-2016-01424, NCT02829918
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9824, NCI-2014-02475, VICC GI1536, NCT02319018
Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 9078, NCI-2015-00684, NCT02451553
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
Recombinant EphB4-HSA Fusion Protein with Standard Chemotherapy Regimens in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-15-5, NCI-2015-00987, NCT02495896
6,8-Bis(benzylthio)octanoic Acid in Treating Patients with Advanced or Metastatic Cholangiocarcinoma that Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 80
Trial IDs: CCCWFU 59212, NCI-2013-00063, NCT01766219
Tremelimumab with Transarterial Chemoembolization, Radiofrequency Ablation, Cryosurgery, or Stereotactic Body Radiation Therapy in Treating Patients with Advanced Liver or Biliary Tract Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0120, NCI-2013-01557, 130120, P121113, NCT01853618
Durvalumab and Tremelimumab with and without Ablative Therapy in Treating Patients with Advanced Liver or Biliary Tract Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0135, NCI-2016-01061, NCT02821754
Start Over